Long acting analogue of somatostatin (Octreotide) for treatment of patients with neurochorioretinitis due to ocular sarcoidosis who failed corticosteroids therapy
Jurowski, P.; Goś, R.; Kunert-Radek, J.
Klinika Oczna 104(3-4): 266-269
2002
ISSN/ISBN: 0023-2157 PMID: 12608317 Document Number: 546173
Neurochorioretinitis due to the course of ocular sarcoidosis is relatively rare case. It usually responds well to conventional treatment with corticosteroids. We want to present the patient effectively treated with long acting analogue of somatostatin (Octreotide), who failed to respond to previous corticosteroids treatment.
Document emailed within 1 workday
Related Documents
Tulassay, Z.; Kisfalvi, K.; Papp, M. 1995: The effect of the long-acting somatostatin analogue octreotide on caerulein-induced pancreatic injuries in rats Zeitschrift für Gastroenterologie 33(2): 99-102De Bois, M.H.; Bosman, C.H.; de Graaf, P.; van Hoogenhuijze, J. 1988: Closure of a high-output external pancreatic fistula by SMS 201-995, a long-acting analogue of somatostatin Netherlands Journal of Medicine 32(5-6): 293-297
Liao, P.-A.; Pan, S.-W.; Chen, C.-Y.; Deng, C.-Y.; Dong, Y.-H. 2023: Prescription Patterns of new use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids International Journal of Chronic Obstructive Pulmonary Disease 18: 553-563
Mystakidou, K.; Katsouda, E.; Tsilika, E.; Smyrniotis, V.; Vassiliou, I.; Tsiatas, M.; Vlahos, L. 2006: Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment Anticancer Research 26(3b): 2325-2328
Müller, M.K.; Breuer, N.F.; Balzer, K.; Goebell, H. 1988: Treatment of chronic non-secretory diarrhea in ileostomy with the long-acting somatostatin analog SMS 201-995 Zeitschrift für Gastroenterologie 26(3): 166-168
Gorden, P.; Comi, R.J.; Maton, P.N.; Go, V.L. 1989: NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut Annals of Internal Medicine 110(1): 35-50
Townsend, L.; Madlon-Kay, D.J. 2015: HelpDesk answers: is it safe to add long-acting β-2 agonists to inhaled corticosteroids in patients with persistent asthma? Journal of Family Practice 64(6): 370-371
VAN DEN Heuvel, B.; Peeters, M.; Hendlisz, A.; VAN DEN Eynde, M.; Machiels, G.; Dero, I.; Geboes, K.; DE Man, M.; Hendrickx, K.; Delaunoit, T.; Monsaert, E.; Vanderstraten, E.; VAN Laethem, J.L.; Lybaert, W.; Holbrechts, S.; Rolfo, C. 2016: Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept Minerva Chirurgica 2016
Anthony, L.B. 1999: Long-acting formulations of somatostatin analogues Italian Journal of Gastroenterology and Hepatology 31(Suppl): S216-S218
Epeirier, J.M.; Marcais, O.; Ramdani, M.; Mastour, M.; Duhamel, O.; Gislon, J. 1994: Treatment of severe gastroduodenal hemorrhages with the analog of somatostatin (octreotide: SMS 201-995) Gastroenterologie Clinique et Biologique 18(6-7): 664-665
Benzi, L.; Marchetti, P.; Carriero, P.L.; Ciccarone, A.M.; Di Cianni, G.; Giannarelli, R.; Giovannitti, M.G.; Navalesi, R. 1987: Long-term therapy with biosynthetic human insulin: importance of short-acting/intermediate-acting insulin ratio on determining efficacy of treatment Drugs under Experimental and Clinical Research 13(5): 321-325
Padberg, W.M.; Morgalla, H.; Buhr, J.; Hild, P.; Schwemmle, K. 1991: Immunosuppressive action of somatostatin and the somatostatin analogue SMS 201-995 and their synergistic effect with low-dose cyclosporine a in organ transplantation Transplantation Proceedings 23(1 Part 1): 348
Whitehouse, I.; Beglinger, C.; Fried, M.; Gyr, K. 1984: The effect of an octapeptide somatostatin analogue (SMS 201-995) and somatostatin-14 (SST-14) on pentagastrin-stimulated gastric acid secretion: a comparative study in man Hepato-Gastroenterology 31(5): 227-229
Döbrönte, Z.; Stöckert, A.; Végh, G.; Varga, L. 1992: Treatment of carcinoid syndrome with a somatostatin analogue Orvosi Hetilap 133(12): 731-734
Inagaki, A. 2016: Safety of Long-acting Injectable Antipsychotics Is Long-acting Injection a High-risk Treatment Option? Seishin Shinkeigaku Zasshi 118(8): 589-597
Bouin, M.ël.; Aoust, L.D.' 2002: Clinical response of an atypical glucagonoma treated with a long-acting somatostatin analog Gastroenterologie Clinique et Biologique 26(10): 926-929
Jaquet, P.; Gunz, G.; Saveanu, A.; Barlier, A.; Dufour, H.; Taylor, J.; Dong, J.; Kim, S.; Moreau, J.P.; Culler, M.D. 2005: BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide Journal of Endocrinological Investigation 28(11 Suppl International): 21-27
Falhammar, H. 2009: Cyclic ectopic Cushing's syndrome and somatostatin analogue treatment New Zealand Medical Journal 122(1294): 92-95
Morali, G.A.; Braverman, D.Z.; Shemesh, D.; Abramovitz, Z.; Jacobsohn, W.Z. 1991: Successful treatment of pancreatic pseudocyst with a somatostatin analogue and catheter drainage American Journal of Gastroenterology 86(4): 515-518
Wintrob, R.M. 1970: Long acting phenothiazines and long term psychotic patients: the role of fluphenazine enanthate in treatment Diseases of the Nervous System 31(Suppl): 50-62